Pharmacokinetics of muzolimine after oral administration with and without aluminium hydroxide in healthy volunteers.
The pharmacokinetics of muzolimine administered with and without aluminium hydroxide was investigated in volunteers (randomized non-blind cross-over study). Six healthy male volunteers aged 20 to 28 years with a mean body weight of 68 +/- 8 kg received 40 mg muzolimine after a standardized breakfast without and with 1760 mg aluminium hydroxide (Aludrox) administered 10 min before breakfast. Muzolimine concentrations were determined in plasma and urine between 0.5 and 48 h post dosing. The data were analysed using a two- or three-compartment open model. The pharmacokinetic parameters of muzolimine, e.g. absorption half-life, peak concentration, time to reach peak concentration, AUC and mean time, obtained with both treatment regimens, did not show any significant difference (analysis of variance). As a conclusion, the pharmacokinetics of muzolimine is not altered by the ingestion of aluminium hydroxide, which might be important for patients with advanced renal failure.
D000328:Adult; D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000494:pharmacology*; D003956:Dialysis; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D009156:Muzolimine / Q000008:administration & dosage / Q000378:metabolism*; D011720:Pyrazoles / Q000378:metabolism*
D011720:Pyrazoles; D009156:Muzolimine; D000536:Aluminum Hydroxide